Replimune Group, Inc. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Replimune's lead product TUDRIQEV (vusolimogene oderparepvec-wtpg) achieved commercial availability in the U.S. on October 6, 2026, for advanced melanoma in combination with nivolumab, with >15 institutions prescribing and >70% of 200 priority accounts engaged. Cash increased from $268.9M (March 31, 2026) to $307.8M (September 30, 2026), driven by $141.0M net proceeds from an August 2026 stock and pre-funded warrant offering plus $15.0M debt draw, offsetting $57.1M Q2 FY2027 net loss. Company projects runway exceeding 12 months.
Why this rating
First commercial product launch is transformational for pre-revenue biotech; $141M equity raise and 12+ month runway materially extend runway. Relative to $234.5M market cap, this represents real trajectory shift, though execution risk remains (confirmatory trial needed for accelerated approval).
Tradability signal
NO TRADE
No trade: positive news with only +1.3% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.48% over 4 hrs, n=250). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $13.02 ▲ 0.93% | at our read · unknown $12.90 | +10 min · unknown $12.70 ▼ 1.55% | +30 min · unknown $12.82 ▼ 0.62% | +1 hr · unknown $13.84 ▲ 7.25% | +4 hrs · unknown $15.12 ▲ 17.21% |
The stock had already moved -0.92% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.